Internal Medicine, Medical Oncology · Naples, FL
NPI
1952509606
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
8350 Sierra Meadows Blvd Fl 2
Naples, FL, 34113
Phone (239) 732-3140
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.0M
615,107 services
Medicare patients, 2024
1,510
Average age 77
Drug cost, 2024
$7.7M
3,101 prescriptions
Company payments, 2025
$15K
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jay Wang was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 159,630 times for 117 patients. In total Jay Wang billed 615,107 services in 163 codes, and Medicare paid $7.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-31.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 159,630 | 117 | $0.27 | $44K |
| J0897 Injection, denosumab, 1 mg | Office | 30,600 | 220 | $20.41 | $625K |
| J1071 Injection, testosterone cypionate, 1 mg | Office | 24,000 | 11 | $0.02 | $422 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 23,600 | 17 | $0.05 | $1,288 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 21,460 | 62 | $6.35 | $136K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 18,800 | 22 | $44.54 | $837K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 14,760 | 15 | $0.22 | $3,203 |
| J0185 Injection, aprepitant, 1 mg | Office | 14,170 | 30 | $1.34 | $19K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 13,200 | 26 | $2.33 | $31K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 4,240 | 16 | $5.90 | $25K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,231 | 74 | $0.09 | $380 |
| 85025 Blood Count | Office | 4,094 | 1,111 | $7.61 | $31K |
| 36415 Venipuncture Blood Collection | Office | 4,036 | 1,218 | $8.65 | $35K |
| J9041 Injection, bortezomib, 0.1 mg | Office | 3,780 | 13 | $1.45 | $5,469 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,274 | 18 | $35.22 | $115K |
By year: 2022 $8.5M for 658,948 services; 2023 $8.2M for 633,388 services; 2024 $7.0M for 615,107 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 4,094 | 1,111 | $7.61 | $31K |
| 36415 Venipuncture Blood Collection | 4,036 | 1,218 | $8.65 | $35K |
| 85045 Blood Count | 209 | 118 | $3.89 | $814 |
| 81003 Clinical Chemistry | 97 | 37 | $2.20 | $213 |
Medicare prescription drug claims, 2024
In 2024, the drug Jay Wang prescribed most often to Medicare patients was Anastrozole, with 275 prescriptions and refills. In total Jay Wang wrote 3,101 Medicare prescriptions that cost $7.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 275 | 775 | 86 | $6,493 |
| Hydroxyurea Generic | 151 | 427 | 47 | $5,089 |
| Ondansetron Odt Ondansetron | 115 | 123 | 78 | $3,195 |
| Eliquis Apixaban | 114 | 183 | 24 | $107K |
| Alprazolam Generic | 107 | 107 | 29 | $1,658 |
| Zolpidem Tartrate Generic | 98 | 98 | 23 | $549 |
| Oxycodone Hcl Generic | 88 | 88 | 18 | $3,266 |
| Revlimid Lenalidomide | 85 | 85 | 16 | $1.7M |
| Levothyroxine Sodium Generic | 70 | 202 | 24 | $917 |
| Xarelto Rivaroxaban | 70 | 138 | 18 | $75K |
| Tamoxifen Citrate Generic | 67 | 198 | 23 | $2,045 |
| Furosemide Generic | 60 | 105 | 27 | $271 |
| Acyclovir Generic | 60 | 112 | 18 | $1,230 |
| Tramadol Hcl Generic | 53 | 55 | 25 | $368 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 52 | 52 | 14 | $2,197 |
Brand drugs: 791 claims; generic drugs: 2,310 claims; opioid claims: 315.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jay Wang $15K ($15K in general payments such as food, travel and fees) from 50 companies. The largest payer was Jazz Pharmaceuticals Inc. with $7,257.
| Company | Payments | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. JAZZ | 14 | $7,257 |
| Deciphera Pharmaceuticals Inc. | 6 | $2,096 |
| AstraZeneca Pharmaceuticals LP AZN | 25 | $601 |
| Pfizer Inc. PFE | 20 | $421 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $352 |
| Merck Sharp & Dohme LLC MRK | 12 | $291 |
| Incyte Corporation INCY | 10 | $254 |
| Daiichi Sankyo Inc. 4568.T | 10 | $236 |
| Celgene Corporation BMY | 8 | $225 |
| BeOne Medicines USA, Inc. ONC | 8 | $208 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.